Salem Capital Management Inc. bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,200 shares of the medical research company’s stock, valued at approximately $207,000.
Several other hedge funds have also made changes to their positions in AMGN. TrimTabs Asset Management LLC raised its stake in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares in the last quarter. American Beacon Advisors Inc. purchased a new stake in shares of Amgen during the first quarter worth approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new stake in shares of Amgen during the first quarter worth approximately $121,000. 78.09% of the stock is owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded up 0.52% during trading on Wednesday, reaching $187.29. The company had a trading volume of 709,488 shares. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The company has a market capitalization of $136.66 billion, a P/E ratio of 17.06 and a beta of 1.35. The firm’s 50 day moving average is $175.99 and its 200-day moving average is $169.31.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter in the previous year, the business earned $2.84 earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities analysts expect that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
Several brokerages recently commented on AMGN. Royal Bank Of Canada began coverage on Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target for the company. Cann reiterated a “buy” rating and set a $203.00 price target (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Deutsche Bank AG reiterated a “hold” rating and set a $174.00 price target (up from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $203.00 price target (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $186.14.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.